Bayer Reports That As Of April 8, 2014 Settlement Negotiations Have Resolved "approximately 8,560 claimants in the U.S. for a total amount of about US$1.74 billion"

(Posted by Tom Lamb at DrugInjuryWatch.com)

_____________________________________________________________________

UPDATE: December 2014 YAZ / Yasmin Litigation Update: Still Over 2000 DVT And/Or PE Cases Not Settled According To Bayer's Most Recent Financial Report

(12/15/14)

_____________________________________________________________________

UPDATE: Summer 2014 Update YAZ / Yasmin / Ocella / Gianvi Litigation: Bayer Reports On Total Settlements And Number Of Pending Claims

(9/12/14)

______________________________________________________________________________

Soon before the first federal court MDL trial was scheduled to start back in January 2012 Bayer decided to begin to attempt to negotiate settlements for YAZ / Yasmin / Ocella / Gianvi blood clot lawsuits, e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE), on a case-by-case basis.

And while Bayer has settled a significant number of these cases over the past two years, there are still thousands of more drospirenone (DRSP) birth control DVT and PE lawsuits that have not been negotiated to a final settlement agreement, yet.

As of early April 2014 there were reportedly about 2000 unresolved YAZ / Yasmin / Ocella / Gianvi claims — and that number apparently does not include the filed and unfiled Beyaz and Safyral blood clot cases, as there is not any mention of those cases by Bayer in recent their recent DRSP drug injury litigation updates.

______________________________________________________________________________

YAZ/Yasmin/Ocella/Gianvi/Beyaz/Safyral
Free Case Evaluation 
Strictly Confidential, No Obligation.

______________________________________________________________________________

From the Stockholders’ Newsletter First Quarter 2014 (PDF document) issued by Bayer, at page 50:

Yasmin™/YAZ™: As of April 8, 2014, the number of claimants in the pending lawsuits and claims in the United States totaled about 3,900 (excluding claims already settled). Claimants allege that they have ­suffered personal injuries, some of them fatal, from the use of Bayer’s drospirenone-containing oral contraceptive products such as Yasmin™ and/or YAZ™ or from the use of Ocella™ and/or Gianvi™, generic versions of Yasmin™ and YAZ™, respectively, marketed by Barr Laboratories, Inc. in the United States.

As of April 8, 2014, Bayer had reached agreements, without admission of liability, to settle the claims of approximately 8,560 claimants in the U.S. for a total amount of about US$1.74 billion. Bayer has only been settling claims in the U.S. for venous clot injuries (deep vein thrombosis or pulmonary embolism) after a case-specific analysis of medical records on a rolling basis. Such injuries are alleged by about 1,920 of the pending unsettled claimants. Bayer will continue to consider the option of settling such individual lawsuits in the U.S. on a case-by-case basis.

Our previous article about this litigation was "YAZ / Yasmin Products Liability Litigation: February 2014 Bayer Information About The Number Of Claims, Lawsuits, And Settlements", which included Bayer's report that as of February 10, 2014 venous clot injuries (deep vein thrombosis or pulmonary embolism) were alleged by about 1,950 of the pending unsettled claimants.

The litigation update article before that was titled "During 2013 Bayer Has Had More Than 2000 YAZ / Yasmin Lawsuits For Blood Clots That Are Not Settled".

In re-reading those articles again, now, it seems that Bayer's settlement efforts have slowed down over the past year, for whatever reason(s).

______________________________________________________________________________

DrugInjuryLaw.com: Current Legal And Medical Information About Prescription Drug Side Effects  (All website content by attorney Tom Lamb)

Drug Injury Case Evaluation – Free & Confidential  (Legal case review done by attorney Tom Lamb)